文献速递心力衰竭与心肌病血脂与心血管预防

APOL1高风险基因型与绝经后非裔美国女性射血分数保留心衰的关联

Association of APOL1 With Heart Failure With Preserved Ejection Fraction in Postmenopausal African American Women.
PubMed 文献 · JAMA Cardiol · 2018-01-01

中位随访11.0年后,高风险携带者(12.3%)的HFpEF住院风险显著增加58%(HR 1.58,95%CI 1.03-2.41),但校正基线eGFR后关联减弱且不再显著(HR 1.50,95%CI 0.98-2.30)。未见与冠心病、卒中或死亡的关联。

要点

  • APOL1高风险基因型与HFpEF住院风险增加相关,部分由基线肾功能介导。
  • 未发现APOL1高风险基因型与冠心病、卒中或死亡相关。
  • 在绝经后非裔美国女性中,APOL1高风险携带者高血压和eGFR降低更常见。

核心结论

  • APOL1高风险基因型携带与绝经后非裔美国女性HFpEF住院风险增加相关,部分由基线肾功能解释。
  • 未支持APOL1高风险基因型与冠心病、卒中或死亡的关联。

研究设计与样本

  • APOL1变异通过基因分型或全外显子组测序推断。

主要发现

  • 高风险APOL1携带者(n=1370,12.3%)高血压患病率、降脂药使用比例更高,eGFR更低。
  • 平均随访11.0年,高风险携带者HFpEF住院发生率高于低风险携带者,其他结局无差异。
  • 校正模型中,高风险携带者HFpEF住院风险增加58%(HR 1.58,95%CI 1.03-2.41)。
  • 校正基线eGFR后,HFpEF关联减弱且不再显著(HR 1.50,95%CI 0.98-2.30)。

临床怎么用

  • 对绝经后非裔美国女性,APOL1高风险基因型可提示HFpEF风险增加,尤其需关注基线肾功能。
  • 不推荐基于APOL1基因型评估冠心病、卒中或死亡风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: APOL1 genotypes are associated with kidney diseases in African American individuals and may influence cardiovascular disease and mortality risk, but findings have been inconsistent. OBJECTIVE: To discern whether high-risk APOL1 genotypes are associated with cardiovascular disease and stroke in postmenopausal African American women, who are at high risk for these outcomes. DESIGN, SETTING, AND PARTICIPANTS: The Women's Health Initiative is a prospective cohort that enrolled 161 838 postmenopausal women into clinical trials and an observational study between 1993 and 1998. This study includes 11 137 African American women participants who had a clinical event from enrollment to June 2014. Data analyses were completed from January 2017 to August 2017. EXPOSURES: The variants of APOL1 were genotyped or imputed from whole-exome sequencing. MAIN OUTCOMES AND MEASURES: Incident coronary heart disease, stroke and heart failure subtypes, and overall and cause-specific mortality were adjudicated from hospital records and death certificates. Estimated incidence rates were determined for each outcome and hazard ratios (HR) and 95% CIs for the associations of APOL1 groups with outcomes. RESULTS: The mean (SD) age of participants was 61.7 (7.1) years. Carriers of high-risk APOL1 variants (n = 1370; 12.3%) had higher prevalence of hypertension, use of cholesterol-lowering medications, and reduced estimated glomerular filtration rate (eGFR). After a mean (SD) of 11.0 (3.6) years, carriers of high-risk APOL1 variants had a higher incidence rate of hospitalized heart failure with preserved ejection fraction (HFpEF) than low-risk carriers did but showed no differences for other outcomes. In adjusted models, there was a significant 58% increased hazard of hospitalized HFpEF (HR, 1.58 [95% CI, 1.03-2.41]) among carriers of high-risk APOL1 variants compared with carriers of low-risk APOL1 variants. The association with HFpEF was attenuated (HR = 1.50 [95% CI, 0.98-2.30]) and no longer significant when adjusting for baseline eGFR. CONCLUSIONS AND RELEVANCE: Status as a carrier of a high-risk APOL1 genotype was associated with HFpEF hospitalization among postmenopausal women, which is partly accounted for by baseline kidney function. These findings do not support an association of high-risk APOL1 genotypes with coronary heart disease, stroke, or mortality in postmenopausal African American women.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Franceschini N, Kopp JB, Barac A, et al. Association of APOL1 With Heart Failure With Preserved Ejection Fraction in Postmenopausal African American Women. JAMA Cardiol. 2018. PMID: 29971324. doi:10.1001/jamacardio.2018.1827

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。